These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38721770)

  • 41. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.
    Zhang J; Tang P; Zou L; Zhang J; Chen J; Yang C; He G; Liu B; Liu J; Chiang CM; Wang G; Ye T; Ouyang L
    J Med Chem; 2021 Dec; 64(24):18025-18053. PubMed ID: 34908415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail.
    Lu L; Chen Z; Lin X; Tian L; Su Q; An P; Li W; Wu Y; Du J; Shan H; Chiang CM; Wang H
    Cell Death Differ; 2020 Jan; 27(1):255-268. PubMed ID: 31114028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A mitochondria-targeted thiazoleorange-based photothermal agent for enhanced photothermal therapy for tumors.
    Bian W; Pan Z; Wang Y; Long W; Chen Z; Chen N; Zeng Y; Yuan J; Liu X; Lu YJ; He Y; Zhang K
    Bioorg Chem; 2021 Aug; 113():104954. PubMed ID: 34023651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
    Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
    PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
    Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
    Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atomistic insights into the selective therapeutic activity of 6-(2,4-difluorophenoxy)-5-((ethylmethyl)pyridine-3-yl)-8-methylpyrrolo[1,2-a]pyrazin-1(2H)-one towards bromodomain-containing proteins.
    Akawa OB; Soremekun OS; Olotu FA; Soliman MES
    Comput Biol Chem; 2021 Dec; 95():107592. PubMed ID: 34710811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel acceptor-donor-acceptor structured molecule-based nanosystem for tumor mild photothermal therapy.
    Fan W; He Y; Hu P; Liu L; Yang X; Ge T; Jin K; Mou X; Cai Y
    J Colloid Interface Sci; 2024 Sep; 670():762-773. PubMed ID: 38788443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
    Zhang F; Wu Z; Chen P; Zhang J; Wang T; Zhou J; Zhang H
    Bioorg Med Chem; 2020 Jan; 28(1):115228. PubMed ID: 31813613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
    Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
    Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
    [No Abstract]   [Full Text] [Related]  

  • 50. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRD4 as a therapeutic target for atrial fibrosis and atrial fibrillation.
    Song S; Yuan J; Fang G; Li Y; Ding S; Wang Y; Wang Q
    Eur J Pharmacol; 2024 Aug; 977():176714. PubMed ID: 38849043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.
    Watts E; Heidenreich D; Tucker E; Raab M; Strebhardt K; Chesler L; Knapp S; Bellenie B; Hoelder S
    J Med Chem; 2019 Mar; 62(5):2618-2637. PubMed ID: 30789735
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A patent review of BRD4 inhibitors (2013-2019).
    Lu T; Lu W; Luo C
    Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
    [No Abstract]   [Full Text] [Related]  

  • 56. The therapeutic potential of BRD4 in cardiovascular disease.
    Lin S; Du L
    Hypertens Res; 2020 Oct; 43(10):1006-1014. PubMed ID: 32409773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
    Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
    Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression.
    Zheng J; Zhang Y; Cai S; Dong L; Hu X; Chen MB; Zhu YH
    Cancer Lett; 2020 Apr; 476():129-139. PubMed ID: 32081805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
    Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
    ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.